Ocumension climbs 7% on NMPA approval for implant productionMarket Movers·Oct 28, 2026 at 05:14 AM014770.00%
Ocumension Phase III Myopia Drug OT-101 Hits Primary Goal in China CohortTip Ranks·Oct 20, 2026 at 12:38 AM014770.00%
Ocumension Biopharma drops 2% in Hong Kong on glaucoma drug filingHK Stock Market Update·Sep 22, 2026 at 01:43 AM014770.00%
Nicox Announces NCX 470 NDA in China Accepted for ReviewGlobeNewswire·Sep 11, 2026 at 05:30 AM014770.00%
Ocumension says China NMPA accepts OT-301 glaucoma drug applicationPUBT·Sep 10, 2026 at 11:00 PM014770.00%
Ocumension completes enrollment in China Phase III trial of dry eye drug OT-211PUBT·Sep 2, 2026 at 12:13 PM014770.00%
Goldman Sachs Sticks to Their Hold Rating for Ocumension Therapeutics (1477)Tip Ranks·Sep 2, 2026 at 10:56 AM014770.00%
Ocumension says China regulator accepts domestic filing for dexamethasone eye injection OT-502PUBT·Sep 1, 2026 at 11:58 AM014770.00%
